Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
Conclusion Less than one half (43.5%) of patients with clinical indications received formal genetic counseling. There is a large gap between mandates for timely pretest formal genetic counseling in higher-risk patients and the reality of practice today. PMID: 29528794 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 12, 2018 Category: Cancer & Oncology Authors: Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW Tags: J Clin Oncol Source Type: research

US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
Conclusion To our knowledge, this review is the largest analysis to date of the BO subgroup of MBC and suggests this subgroup may have a distinct natural history. There also seems to be a difference in how the local investigators assessed progression events in the BO subgroup when compared with the other two groups. PMID: 29522361 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 9, 2018 Category: Cancer & Oncology Authors: Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R Tags: J Clin Oncol Source Type: research

Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.
CONCLUSIONS: Because second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully. PMID: 29520523 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 8, 2018 Category: Cancer & Oncology Authors: Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K Tags: Int J Clin Oncol Source Type: research

Do FHIT gene alterations play a role in human solid tumors?
Abstract The fragile histidine triad (FHIT) gene encloses an active common chromosomal fragile site, FRA3B. This gene is known to be associated with genomic instability, apoptosis and DNA damage. FHIT disturbances have been related to carcinogenesis in different types of human tumor. Despite this, there are some controversies about the exact role of the FHIT gene in relation to tumor biology. Several pieces of evidence support the hypothesis that FHIT acts as a tumor suppressor gene. A loss or decrease in the Fhit protein expression appears to be related to tumor progression, poor prognostic factors and lower surv...
Source: Clinical Breast Cancer - March 8, 2018 Category: Cancer & Oncology Authors: Silveira Zavalhia L, Weber Medeiros A, Oliveira Silva A, Vial Roehe A Tags: Asia Pac J Clin Oncol Source Type: research

Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab.
We describe a 59-year-old woman with a history of breast carcinoma and bone metastasis who was prescribed denosumab for 4 years. The patient had no history of any prior bisphosphonate use. Bone scintigraphy showed an abnormal uptake in the right femur, which was confirmed as an impending AFF or atypical femoral stress reaction. In oncological patients receiving long-term denosumab, AFF should be included as a differential diagnosis for focal femoral findings.This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in...
Source: Clinical Breast Cancer - March 7, 2018 Category: Cancer & Oncology Authors: Sugihara T, Koizumi M, Hayakawa K, Ito Y, Sata N Tags: Clin Nucl Med Source Type: research

Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985-2004).
CONCLUSIONS: In our study, women diagnosed with breast cancer had higher long-term probability to die from breast cancer than from other causes. The improvements in treatment and the lead-time bias in detecting cancer in an early stage resulted in a reduction of 19% in the risk of death between diagnostic periods. PMID: 29511947 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Clèries R, Ameijide A, Buxó M, Martínez JM, Marcos-Gragera R, Vilardell ML, Carulla M, Yasui Y, Vilardell M, Espinàs JA, Borràs JM, Galceran J, Izquierdo À Tags: Clin Transl Oncol Source Type: research

Breast cancer: Fibroblast subtypes alter the microenvironment.
PMID: 29508858 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Sidaway P Tags: Nat Rev Clin Oncol Source Type: research

Genetic Variations, Exposure to Persistent Organic Pollutants and Breast Cancer Risk: A Greenlandic Case-Control Study.
This article is protected by copyright. All rights reserved. PMID: 29510000 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Wielsøe M, Eiberg H, Ghisari M, Kern P, Lind O, Bonefeld-Jørgensen EC Tags: Basic Clin Pharmacol Toxicol Source Type: research

CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.
CONCLUSIONS: Our study demonstrates that miR-10b-CADM2-FAK/AKT axis plays an important role in HCC metastasis, which might be a novel potential therapeutic option for HCC treatment. PMID: 29506532 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 5, 2018 Category: Cancer & Oncology Authors: Li D, Zhang Y, Zhang H, Zhan C, Li X, Ba T, Qiu Z, E F, Lv G, Zou C, Wang C, Si L, Zou C, Li Q, Gao X Tags: J Exp Clin Cancer Res Source Type: research

Multiple primary non-breast tumors in breast cancer survivors.
CONCLUSIONS: Older age represents the major risk of developing a second primary non-breast cancer, excluding ovarian cancer. Clinical surveillance is required to prevent ovarian and thyroid cancers, respectively, in patients with positive family history, triple negative, G3 breast cancer and during hormonal therapy treatment in postmenopausal status. PMID: 29502170 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2018 Category: Cancer & Oncology Authors: Corso G, Veronesi P, Santomauro GI, Maisonneuve P, Morigi C, Peruzzotti G, Intra M, Sacchini V, Galimberti V Tags: J Cancer Res Clin Oncol Source Type: research

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.
Conclusions: The frequency of 13 causative founder variants in Podkarpacie was lower than in other regions of Poland. Testing of three BRCA1 mutations (c.5266dupC, c.181 T > G, c.676delT) should be considered a sensitive test panel. PMID: 29492181 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 2, 2018 Category: Cancer & Oncology Authors: Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubiński J, Narod SA, Gronwald J Tags: Hered Cancer Clin Pract Source Type: research

Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge.
Abstract Breast cancer is the leading cause of cancer mortality among women in developing countries. Timely and accurate histopathological diagnosis of breast cancer is critical to delivering high-quality breast cancer care to patients in low- and middle-income countries (LMIC). The most important prognostic factors in breast cancer along with tumor size and nodal status are tumor grade, estrogen receptor status, as well as HER2 status in countries where specific targeted therapies are available. In addition, detailed and complete cancer registry data are needed to assess a country's disease burden and guide disea...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Martei YM, Pace LE, Brock JE, Shulman LN Tags: Clin Lab Med Source Type: research

Core Needle Biopsy of the Breast: An Evaluation of Contemporary Data.
This article highlights contemporary diagnostic criteria and outcome data that would support an evidence-based approach to the management of these nonmalignant lesions of the breast diagnosed on CNB. PMID: 29413652 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Calhoun BC Tags: Surg Pathol Clin Source Type: research

Lobular Carcinoma In Situ.
Abstract Lobular carcinoma in situ (LCIS) is a risk factor and a nonobligate precursor of breast carcinoma. The relative risk of invasive carcinoma after classic LCIS diagnosis is approximately 9 to 10 times that of the general population. Classic LCIS diagnosed on core biopsy with concordant imaging and pathologic findings does not mandate surgical excision, and margin status is not reported. The identification of variant LCIS in a needle core biopsy specimen mandates surgical excision, regardless of radiologic-pathologic concordance. The presence of variant LCIS close to the surgical margin of a resection specim...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Wen HY, Brogi E Tags: Surg Pathol Clin Source Type: research

Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results.
Abstract Ancillary testing in breast cancer has become standard of care to determine what therapies may be most effective for individual patients with breast cancer. Single-marker tests are required on all newly diagnosed and newly metastatic breast cancers. Markers of proliferation are also used, and include both single-marker tests like Ki67 as well as panel-based gene expression tests, which have made more recent contributions to prognostic and predictive testing in breast cancers. This review focuses on pathologist interpretation of these ancillary test results, with a focus on expected versus unexpected resul...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Allison KH Tags: Surg Pathol Clin Source Type: research

Genotype-Phenotype Correlations in Breast Cancer.
Abstract Only a few breast cancer histologic subtypes harbor distinct genetic alterations that are associated with a specific morphology (genotype-phenotype correlation). Secretory carcinomas and adenoid cystic carcinomas are each characterized by recurrent translocations, and invasive lobular carcinomas frequently have CDH1 mutations. Solid papillary carcinoma with reverse polarity is a rare breast cancer subtype with a distinctive morphology and recently identified IDH2 mutations. We review the clinical and pathologic features and underlying genetic alterations of those breast cancer subtypes with established ge...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Marotti JD, Schnitt SJ Tags: Surg Pathol Clin Source Type: research

Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Abstract Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the brea...
Source: Clinical Breast Cancer - February 9, 2018 Category: Cancer & Oncology Authors: Bossuyt V Tags: Surg Pathol Clin Source Type: research

The Drug-Drug Interaction Profile of Presatovir.
This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics. Presatovir plasma exposures (maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P-gp, BCRP, or OATP1B1/1B3. As expected, based on the role of CYP3A in...
Source: Clinical Breast Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Xin Y, Weng W, Murray BP, Eisenberg EJ, Chien JW, Ling J, Silverman JA Tags: J Clin Pharmacol Source Type: research

Breast cancer: Recurrent fusions in endocrine-resistant disease.
PMID: 29405202 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 6, 2018 Category: Cancer & Oncology Authors: Romero D Tags: Nat Rev Clin Oncol Source Type: research

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors. PMID: 29401002 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J Tags: J Clin Oncol Source Type: research

Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
CONCLUSIONS: Despite the results achieved at somatic levels by other researchers, these were not confirmed in our study at the germline level. Our results show the need to establish more predictive CpG sites in the BRCA promoter regions to optimize the MS-MLPA assay for the detection of germline hypermethylation as an effective pre-screening tool for whole-BRCA genetic analysis in HBOC, because we can not rule out the existence of germline promoter hypermethylation in BRCA. PMID: 29404838 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Rodríguez-Balada M, Roig B, Melé M, Salvat M, Martorell L, Borràs J, Gumà J Tags: Clin Transl Oncol Source Type: research

Predictive factors of satisfaction and quality of life after immediate breast reconstruction using the BREAST-Q ©.
CONCLUSIONS: The type of treatment and lymphedema modify the patients' quality of life. Nicotine dependence is associated with lower satisfaction with the breast and with the outcome. RELEVANCE TO CLINICAL PRACTICE: This study suggests the need for multi-disciplinary attention during the first year of adjuvant treatment despite the benefits of immediate reconstruction. It shows the need for preoperative assessment of the level of nicotine dependence, anxiety and depression of smoking patients before preoperative counseling. This article is protected by copyright. All rights reserved. PMID: 29396899 [PubMed - as s...
Source: Clinical Breast Cancer - February 3, 2018 Category: Cancer & Oncology Authors: Cereijo-Garea C, Pita-Fernández S, Acea-Nebril B, Rey-Villar R, García-Novoa A, Varela-Lamas C, Builes-Ramirez S, Seoane-Pillado T, Balboa-Barreiro V Tags: J Clin Nurs Source Type: research

Selenium in infant formula milk.
Abstract Formula-based animal milk is an alternative source of infant nutrition in many cases when breastfeeding is unacceptable or inaccessible; however, these replacements often have low selenium levels. The composition of infant formula milk should be as close as possible to that of human breast milk, both in content and chemical speciation. Selenium is an essential trace element for infants. Generally, human breast milk is the ideal food to ensure adequate infant Se intake. However, to date, sodium selenite or sodium selenate has been used as selenium supplementation in infant formula milk in most countries. T...
Source: Clinical Breast Cancer - February 1, 2018 Category: Cancer & Oncology Authors: He MJ, Zhang SQ, Mu W, Huang ZW Tags: Asia Pac J Clin Nutr Source Type: research

Label-Free Quantitative Proteomic Screening of Candidate Plasma Biomarkers for the Prognosis of Breast Cancer with Different Lymph Node Statuses.
CONCLUSIONS AND CLINICAL RELEVANCE: The present dataset provides a list of candidate biomarkers that could be used for early differentiation diagnosis and prognosis of breast cancer with lymph node metastasis. This article is protected by copyright. All rights reserved. PMID: 29384592 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Chen L, Zhao W, He J, Li L, Meng D, Cai D, Yu J, Chen D, Wu Y, Zhou T Tags: Proteomics Clin Appl Source Type: research

Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
Conclusion These findings support current recommendations for systemic imaging in the setting of locoregional recurrence, particularly for patients with lymph node or chest wall recurrences. Because most patients with isolated locoregional recurrence will be recommended locoregional treatment, early identification of distant metastases through routine systemic imaging may spare them treatments unlikely to extend their survival. PMID: 29384721 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Vanness DJ, Yu M, McKellar D, Winchester DP, Greenberg CC, Alliance/American College of Surgeons Clinical Research Program Cancer Care Delivery Research Breast Cancer Surveillance Working Grou Tags: J Clin Oncol Source Type: research

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Abstract Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype. PMID: 29385237 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 31, 2018 Category: Cancer & Oncology Authors: Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE Tags: Clin Pharmacol Ther Source Type: research

Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Abstract Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. The risk of bias of selected studies was evaluated and the relevant data items were extracted, summarized and analyzed. A total of 21 studies were discussed in this review r...
Source: Clinical Breast Cancer - January 30, 2018 Category: Cancer & Oncology Authors: Nahm N, Mee S, Marx G Tags: Asia Pac J Clin Oncol Source Type: research

Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds.
Conclusion: All women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing irrespective of which causative genetic variants have been demonstrated in their relatives. PMID: 29371908 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 28, 2018 Category: Cancer & Oncology Authors: Dominguez-Valentin M, Evans DGR, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P, Hovig E Tags: Hered Cancer Clin Pract Source Type: research

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC. PMID: 29373071 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 26, 2018 Category: Cancer & Oncology Authors: Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J Tags: J Clin Oncol Source Type: research

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Conclusion Equivalence for efficacy was demonstrated between SB3 and TRZ on the basis of the ratio of bpCR rates. Safety and immunogenicity were comparable. PMID: 29373094 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 26, 2018 Category: Cancer & Oncology Authors: Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M, Semiglazov V, Song S, Lim J Tags: J Clin Oncol Source Type: research

Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study.
Abstract Purpose Being diagnosed with cancer causes major psychological distress; however, a majority of patients lack psychological support during this critical period. Internet interventions help patients overcome many barriers to seeking face-to-face support and may thus close this gap. We assessed feasibility and efficacy of Web-based stress management (STREAM [Stress-Aktiv-Mindern]) for newly diagnosed patients with cancer. Patients and Methods In a randomized controlled trial, patients with cancer who had started first-line treatment within the previous 12 weeks were randomly assigned to a therapist-guided W...
Source: Clinical Breast Cancer - January 25, 2018 Category: Cancer & Oncology Authors: Urech C, Grossert A, Alder J, Scherer S, Handschin B, Kasenda B, Borislavova B, Degen S, Erb J, Faessler A, Gattlen L, Schibli S, Werndli C, Gaab J, Berger T, Zumbrunn T, Hess V Tags: J Clin Oncol Source Type: research

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
TP, Ejlertsen B Abstract Purpose The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of postmenopausal women with hormone receptor-positive early breast cancer treated with 5 years of endocrine therapy alone. Patients and Methods Using the population-based Danish Breast Cancer Cooperative Group database, follow-up data were collected on all patients diagnosed from 2000 through 2003 who, by nationwide guidelines,...
Source: Clinical Breast Cancer - January 25, 2018 Category: Cancer & Oncology Authors: Lænkholm AV, Jensen MB, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, Ferree S, Schaper C, Nielsen TO, Haffner T, Kibøl T, Møller Talman ML, Bak Jylling AM, Tabor TP, Ejlertsen B Tags: J Clin Oncol Source Type: research

Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
Conclusion The tailored and interactive iCanDecide Web site, which focused on knowledge building and values clarification, positively affected high-quality decisions largely by improving knowledge compared with static online information. To be effective, future patient-facing decision tools should be integrated into the clinical workflow to improve decision making. PMID: 29364772 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 24, 2018 Category: Cancer & Oncology Authors: Hawley ST, Li Y, An LC, Resnicow K, Janz NK, Sabel MS, Ward KC, Fagerlin A, Morrow M, Jagsi R, Hofer TP, Katz SJ Tags: J Clin Oncol Source Type: research

Exogenous reproductive hormone use in breast cancer survivors and previvors.
Abstract Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure f...
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Vaz-Luis I, Partridge AH Tags: Nat Rev Clin Oncol Source Type: research

Survivin is a negative prognostic factor in malignant pleural effusion.
ro F, Otero-Candelera R Abstract SURVIVIN: is a well-known member of the inhibitor of apoptosis family, and has been related with increased tumour aggressivity, both in tissue and in pleural fluid. OBJECTIVES: In patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. METHODS: We investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 ...
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Arellano-Orden E, Romero-Romero B, Sánchez-López V, Martín-Juan J, Rodríguez-Panadero F, Otero-Candelera R Tags: Eur J Clin Invest Source Type: research

Transforming growth factor beta 1 (TGF β1) polymorphisms and haplotype structures have dual roles in breast cancer pathogenesis.
CONCLUSION: The present study indicates that TGFB1 variants have subtype-specific roles in BC and may switch from tumor suppressor to promoter during tumor development, consistent with TGFβ1 dual role in BC pathogenesis. PMID: 29362917 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Vitiello GAF, Guembarovski RL, Hirata BKB, Amarante MK, de Oliveira CEC, de Oliveira KB, Cebinelli GCM, Guembarovski AL, Campos CZ, Watanabe MAE Tags: J Cancer Res Clin Oncol Source Type: research

Proliferation-associated miRNAs-494, -205, -21 and -126 detected by in situ hybridization: expression and prognostic potential in breast carcinoma patients.
CONCLUSIONS: The present paper reports for the first time on the prognostic value of miRNA-494 in invasive breast cancer. Particularly, detection of miRNA-494 could benefit patients with node-negative breast cancer in identifying subgroups with aggressive disease. Based on our experience, the developed automatic ISH method to visualize altered levels of miRNAs-494, -205, -21 and -126 could be applied to routine pathology diagnostics providing that conditions of tissue treatment, especially fixation delays, are managed. PMID: 29362919 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 23, 2018 Category: Cancer & Oncology Authors: Gurvits N, Autere TA, Repo H, Nykänen M, Kuopio T, Kronqvist P, Talvinen K Tags: J Cancer Res Clin Oncol Source Type: research

Breast Cancer Stage at Diagnosis in a New Jersey Cancer Education and Early Detection Site.
This study will provide a first snapshot of the effectiveness of the New Jersey program, by comparing stage at diagnosis for enrollees as compared with nonenrollees who received definitive treatment for breast cancer at the same academic medical center. MATERIALS AND METHODS: A retrospective analysis of 5 years of breast cancer data abstracted from the Cancer Registry of a large urban hospital in the Northeast United States. Bivariate analysis and logistic regression were utilized. RESULTS: One thousand forty women were screened for and diagnosed with breast cancer at this site; they were more likely to be racially (P
Source: Clinical Breast Cancer - January 22, 2018 Category: Cancer & Oncology Authors: Jerome-D'Emilia B, Kushary D, Burrell SA, Suplee PD, Hansen K Tags: Am J Clin Oncol Source Type: research

Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
Abstract Purpose Metabolic syndrome is associated with an increased risk of cardiovascular disease, type 2 diabetes, and breast cancer recurrence in survivors of breast cancer. This randomized controlled trial assessed the effects of a 16-week combined aerobic and resistance exercise intervention on metabolic syndrome, sarcopenic obesity, and serum biomarkers among ethnically diverse, sedentary, overweight, or obese survivors of breast cancer. Methods Eligible survivors of breast cancer (N = 100) were randomly assigned to exercise (n = 50) or usual care (n = 50). The exercise group participated in supervised moder...
Source: Clinical Breast Cancer - January 22, 2018 Category: Cancer & Oncology Authors: Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE Tags: J Clin Oncol Source Type: research

Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial.
This study aimed to test a group psychosocial intervention focused on improving disturbances of body image (BI), sexual functioning, and quality of life in breast cancer (BC) survivors. Methods A prospective, randomized controlled trial was conducted to assess the efficacy of an 8-week group intervention in women after BC treatment. The manual-based intervention combined two powerful ingredients: expressive guided-imagery exercises integrated within a model of group-therapy principles. The intervention facilitates exploration of identity, the development of new self-schemas, and personal growth. In addition, the interventi...
Source: Clinical Breast Cancer - January 22, 2018 Category: Cancer & Oncology Authors: Esplen MJ, Wong J, Warner E, Toner B Tags: J Clin Oncol Source Type: research

Does breast density measured through population-based screening independently increase breast cancer risk in Asian females?
Abstract Purpose: The purpose of this study was to investigate the effects of breast density on breast cancer risk among women screened via a nationwide mammographic screening program. Patients and methods: We conducted a nested case-control study for a randomly selected population of 1,561 breast cancer patients and 6,002 matched controls from the National Cancer Screening Program. Breast density was measured and recorded by two independent radiologists using the Breast Imaging Reporting and Data System (BI-RADS). Associations between BI-RADS density and breast cancer risk were evaluated according to screeni...
Source: Clinical Breast Cancer - January 20, 2018 Category: Cancer & Oncology Authors: Park B, Cho HM, Lee EH, Song S, Suh M, Choi KS, Kang BJ, Ko K, Yi A, Jung HK, Cha JH, Jun JK Tags: Clin Epidemiol Source Type: research

Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.
Abstract There has been tremendous progress in detection of breast cancer in postmenopausal women, resulting in two-thirds of women surviving more than 20 years after treatment. However, breast cancer remains the leading cause of cancer-related deaths in premenopausal women. Breast cancer is increasing in younger women due to changes in life-style as well as those at high risk as carriers of mutations in high-penetrance genes. Premenopausal women with breast cancer are more likely to be diagnosed with aggressive tumours and therefore have a lower survival rate. Mammography plays an important role in detecting...
Source: Clinical Breast Cancer - January 20, 2018 Category: Cancer & Oncology Authors: Shaheed SU, Tait C, Kyriacou K, Linforth R, Salhab M, Sutton C Tags: Clin Proteomics Source Type: research

BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway.
Conclusions: The spectrum of BRCA1 and BRCA2 mutations in the carrier population at Norway's largest cancer genetics clinic is diverse, and with a weaker founder effect than previously described. As a consequence, retesting the families that previously have been tested with specific tests/founder mutation tests should be a prioritised strategy to find more mutation positive families and possibly prevent cancer in healthy relatives. PMID: 29339979 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 18, 2018 Category: Cancer & Oncology Authors: Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L Tags: Hered Cancer Clin Pract Source Type: research

Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Abstract Purpose The 21-gene recurrence score (RS) breast cancer assay is clinically used to quantify risk of 10-year distant recurrence by category (low,
Source: Clinical Breast Cancer - January 17, 2018 Category: Cancer & Oncology Authors: Holowatyj AN, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS Tags: J Clin Oncol Source Type: research

Epstein Barr virus and invasive mammary carcinomas: EBNA, EBERs and molecular profile in a population of West Algeria.
The objective of this study is to determine the association of EBV infection with infiltrating ductal carcinomas (IDC). This descriptive study was carried out in the laboratory of developmental biology and differentiation, from 2012 to 2014. Of 39 cases, we determined the clinicopathological characteristics of the population. Of the 23 cases of IDC, we implemented the techniques Elisa, immunohistochemistry and in situ hybridization. To determine the serological profile, overexpression of onco-proteins EBNA-1, HER2, the mitotic index Ki67 and detection of the presence of the viral genome. The mean age is 57.40±4, SBR...
Source: Clinical Breast Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Yahia R, Zaoui C, Derbale W, Boudi H, Chebloune Y, Sahraoui T, Elkebir FZ Tags: Ann Biol Clin (Paris) Source Type: research

Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
CONCLUSIONS: Our work provides experimental evidence on the association of 6PGD with poor prognosis in breast cancer and suggests that 6PGD inhibition may represent a potential therapeutic strategy to augment chemotherapy efficacy in breast cancer. PMID: 29340974 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 16, 2018 Category: Cancer & Oncology Authors: Yang X, Peng X, Huang J Tags: Clin Transl Oncol Source Type: research

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL. PMID: 29328860 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 12, 2018 Category: Cancer & Oncology Authors: Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ Tags: J Clin Oncol Source Type: research

Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
We examined the potential of the reversible P2Y12 inhibitor ticagrelor, an agent used clinically to prevent cardiovascular and cerebrovascular events, to reduce tumor growth and metastasis. In vitro, MCF-7, MDA-MB-468, and MDA-MB-231 human mammary carcinoma cells exhibited decreased interaction with platelets treated with ticagrelor compared to untreated platelets. Prevention of tumor cell-platelet interactions through pretreatment of platelets with ticagrelor did not improve natural killer cell-mediated tumor cell killing of K562 myelogenous leukemia target cells. Additionally, ticagrelor had no effect on proliferation of...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Gareau AJ, Brien C, Gebremeskel S, Liwski RS, Johnston B, Bezuhly M Tags: Clin Exp Metastasis Source Type: research

Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.
Abstract During epithelial-mesenchymal transition (EMT) epithelial cancer cells trans-differentiate into highly-motile, invasive, mesenchymal-like cells giving rise to disseminating tumor cells. Only few of these disseminated cells successfully metastasize. Immune cells and inflammation in the tumor microenvironment was shown to drive EMT, but few studies investigated the consequences of EMT on tumor immunosurveillance. In addition to initiating metastasis, we demonstrate that EMT confers increased susceptibility to NK cells and contributes, in part, to the inefficiency of the metastatic process. Depletion of NK c...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG Tags: J Clin Invest Source Type: research

High nuclear MSK1 is associated with longer survival in breast cancer patients.
Abstract PURPOSE: Mitogen- and stress-activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested to potentially play a role in breast cancer cell proliferation, cell cycle progression, cell migration, invasion and tumour growth. The aim of the current study was to assess MSK1 protein expression in breast cancer tumour specimens, evaluating its prognostic significance. METHODS: A large cohort of 1902 early stage invasive breast cancer patients was use...
Source: Clinical Breast Cancer - January 11, 2018 Category: Cancer & Oncology Authors: Pu X, Storr SJ, Ahmad NS, Rakha EA, Green AR, Ellis IO, Martin SG Tags: J Cancer Res Clin Oncol Source Type: research